ARC-augmented renal clearance

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2020-2029

  Udy, Andrew A ^a,b   Putt, Michael T ^a   Boots, Robert J ^a,b   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotics; Creatinine clearance; Dosing; eGFR; Glomerular filtration rate; Renal function

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CEFPIROME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; CREATININE; DAPTOMYCIN; DOBUTAMINE; DOPAMINE; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; NORADRENALIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; AUGMENTED RENAL CLEARANCE; BONE INFECTION; BRAIN PERFUSION; BURN; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIET THERAPY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; ENDOCARDITIS; FEBRILE NEUTROPENIA; FLUID RESUSCITATION; GLOMERULUS FILTRATION RATE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYPOALBUMINEMIA; KIDNEY CLEARANCE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SEPSIS; SOLUTE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRAUMATIC BRAIN INJURY; TREATMENT FAILURE; URINARY EXCRETION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; KIDNEY; SEPSIS;

EID: 84855220945     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808446     Document Type: Article

References (161)

1. Roberts, J.A.; Lipman, J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet, 2006, 45(8), 755-773.
2. Roberts, J.A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med., 2009, 37(3), 840-851.
3. Udy, A.; Roberts, J.A.; Boots, R.J.; Lipman, J. You only find what you look for: the importance of high creatinine clearance in the critically ill. Anaesth Intensive Care, 2009, 37(1), 11-13.
4. Ibrahim, E.H.; Sherman, G.; Ward, S.; Fraser, V.J.; Kollef, M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest, 2000, 118(1), 146-155.
5. Kollef, M.H.; Sherman, G.; Ward, S.; Fraser, V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest, 1999, 115(2), 462-474.
6. Kumar, A.; Roberts, D.; Wood, K.E.; Light, B.; Parrillo, J.E.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S.; Taiberg, L.; Gurka, D.; Kumar, A.; Cheang, M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med., 2006, 34(6), 1589-1596.
7. MacArthur, R.D.; Miller, M.; Albertson, T.; Panacek, E.; Johnson, D.; Teoh, L.; Barchuk, W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis., 2004, 38(2), 284-288.
8. Udy, A.A.; Roberts, J.A.; Boots, R.J.; Paterson, D.L.; Lipman, J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet., 2010, 49(1), 1-16.
9. Stevens, L.A.; Coresh, J.; Greene, T.; Levey, A.S. Assessing kidney function--measured and estimated glomerular filtration rate. N. Engl. J. Med., 2006, 354(23), 2473-2483.
10. Gross, A.S.; McLachlan, A.J.; Minns, I.; Beal, J.B.; Tett, S.E. Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br. J. Clin. Pharmacol., 2001, 51(6), 547-555.
11. Angus, B.J.; Smith, M.D.; Suputtamongkol, Y.; Mattie, H.; Walsh, A.L.; Wuthiekanun, V.; Chaowagul, W.; White, N.J. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br. J. Clin. Pharmacol., 2000, 50(2), 184-191.
12. Barbot, A.; Venisse, N.; Rayeh, F.; Bouquet, S.; Debaene, B.; Mimoz, O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med., 2003, 29(9), 1528-1534.
13. Burkhardt, O.; Kumar, V.; Katterwe, D.; Majcher-Peszynska, J.; Drewelow, B.; Derendorf, H.; Welte, T. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J. Antimicrob. Chemother., 2007, 59(2), 277-284.
14. Conil, J.M.; Georges, B.; Mimoz, O.; Dieye, E.; Ruiz, S.; Cougot, P.; Samii, K.; Houin, G.; Saivin, S. Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med., 2006, 32(12), 2063-2066.
15. del Mar Fernandez de Gatta Garcia, M.; Revilla, N.; Calvo, M.V.; Dominguez-Gil, A.; Sanchez Navarro, A. Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med., 2007, 33(2), 279-285.
16. Ikawa, K.; Morikawa, N.; Ikeda, K.; Ohge, H.; Sueda, T.; Suyama, H.; Doi, M.; Kuwabara, M. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy. Chemotherapy, 2008, 54(5), 386-394.
17. Ikawa, K.; Morikawa, N.; Uehara, S.; Monden, K.; Yamada, Y.; Honda, N.; Kumon, H. Pharmacokinetics-pharmacodynamic target attainment analysis of doripenem in infected patients. Int. J. Antimicrob. Agents, 2008, 53(5),1863-1867.
18. Li, C.; Kuti, J.L.; Nightingale, C.H.; Mansfield, D.L.; Dana, A.; Nicolau, D.P. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intraabdominal infection. J. Antimicrob. Chemother., 2005, 56(2), 388-395.
19. Lipman, J.; Wallis, S.C.; Rickard, C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother, 1999, 43(10), 2559-2561.
20. Lipman, J.; Wallis, S.C.; Rickard, C.M.; Fraenkel, D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med., 2001, 27(2), 363-370.
21. Young, R.J.; Lipman, J.; Gin, T.; Gomersall, C.D.; Joynt, G.M.; Oh, T.E. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother, 1997, 40(2), 269-273.
22. Llopis-Salvia, P.; Jimenez-Torres, N.V. Population pharmacokinetic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther., 2006, 31(5), 447-454.
23. Dailly, E.; Le Floch, R.; Deslandes, G.; Pannier, M.; Jolliet, P. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int. J. Antimicrob. Agents, 2008, 31(6), 537-539.
24. Pea, F.; Furlanut, M.; Negri, C.; Pavan, F.; Crapis, M.; Cristini, F.; Viale, P. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study. Antimicrob. Agents Chemother., 2009, 53(5),1863-1867.
25. Lortholary, O.; Tod, M.; Rizzo, N.; Padoin, C.; Biard, O.; Casassus, P.; Guillevin, L.; Petitjean, O. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob. Agents Chemother., 1996, 40(5), 1242-1247.
26. Pea, F.; Brollo, L.; Viale, P.; Pavan, F.; Furlanut, M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J. Antimicrob. Chemother., 2003, 51(4), 971-975.
27. Sunder-Plassmann, G.; Horl, W.H. A critical appraisal for definition of hyperfiltration. Am. J. Kidney Dis., 2004, 43(2), 396.
28. Hoste, E.A.; Damen, J.; Vanholder, R.C.; Lameire, N.H.; Delanghe, J.R.; Van den Hauwe, K.; Colardyn, F.A. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol. Dial Transplant, 2005, 20(4), 747-753.
29. Cockcroft, D.W.; Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron, 1976, 16(1), 31-41.
30. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern Med., 1999, 130(6), 461-470.
31. Martin, J.H.; Fay, M.F.; Ungerer, J.P. eGFR--use beyond the evidence. Med. J. Aust., 2009, 190(4), 197-199.
32. Herrera-Gutierrez, M.E.; Seller-Perez, G.; Banderas-Bravo, E.; Munoz-Bono, J.; Lebron-Gallardo, M.; Fernandez-Ortega, J.F. Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a single-center study. Intensive Care Med., 2007, 33(11), 1900-1906.
33. Conil, J.M.; Georges, B.; Fourcade, O.; Seguin, T.; Lavit, M.; Samii, K.; Houin, G.; Tack, I.; Saivin, S. Assessment of renal function in clinical practice at the bedside of burn patients. Br. J. Clin. Pharmacol., 2007, 63(5), 583-594.
34. Cherry, R.A.; Eachempati, S.R.; Hydo, L.; Barie, P.S. Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients. J. Trauma., 2002, 53(2), 267-271.
35. Martin, J.H.; Fay, M.F.; Udy, A.; Roberts, J.A.; Kirkpatrick, C.M.; Ungerer, J.; Lipman, J. Pitfalls of using estimations of glomerular filtration in an intensive care population. Intern Med. J., 2010, [Epub ahead of print].
36. Poggio, E.D.; Nef, P.C.; Wang, X.; Greene, T.; Van Lente, F.; Dennis, V.W.; Hall, P.M. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am. J. Kidney Dis., 2005, 46(2), 242-252.
37. Snider, R.D.; Kruse, J.A.; Bander, J.J.; Dunn, G.H. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy, 1995, 15(6), 747-753.
38. Lin, J.; Knight, E.L.; Hogan, M.L.; Singh, A.K. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J. Am. Soc. Nephrol., 2003, 14(10), 2573-2580.
39. Poggio, E.D.; Wang, X.; Greene, T.; Van Lente, F.; Hall, P.M. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J. Am. Soc. Nephrol., 2005, 16(2), 459-466.
40. Rule, A.D.; Larson, T.S.; Bergstralh, E.J.; Slezak, J.M.; Jacobsen, S.J.; Cosio, F.G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann. Intern. Med., 2004, 141(12), 929-937.
41. Jelliffe, R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am. J. Nephrol., 2002, 22(4), 320-324.
42. Jones, C.A.; McQuillan, G.M.; Kusek, J.W.; Eberhardt, M.S.; Herman, W.H.; Coresh, J.; Salive, M.; Jones, C.P.; Agodoa, L.Y. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am. J. Kidney Dis., 1998, 32(6), 992-999.
43. Pong, S.; Seto, W.; Abdolell, M.; Trope, A.; Wong, K.; Herridge, J.; Harvey, E.; Kavanagh, B.P. 12-hour versus 24-hour creatinine clearance in critically ill pediatric patients Pediatr Res., 2005, 58(1), 83-88.
44. Sladen, R.N.; Endo, E.; Harrison, T. Two-hour versus 22-hour creatinine clearance in critically ill patients Anesthesiology, 1987, 67(6), 1013-1016.
45. Wells, M.; Lipman, J. Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. S. Afr. J. Surg., 1997, 35(1), 20-23.
46. Wells, M.; Lipman, J. Pitfalls in the prediction of renal function in the intensive care unit. A review. S. Afr. J. Surg., 1997, 35(1), 16-19.
47. Fuster-Lluch, O.; Geronimo-Pardo, M.; Peyro-Garcia, R.; Lizan-Garcia, M. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth. Intensive Care, 2008, 36(5), 674-680.
48. Lipman, J.; Wallis, S.C.; Boots, R.J. Cefepime versus cefpirome: the importance of creatinine clearance Anesth. Analg., 2003, 97(4), 1149-1154.
49. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M.; Sibbald, W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest, 1992, 101(6), 1644-1655.
50. Levy, M.M.; Fink, M.P.; Marshall, J.C.; Abraham, E.; Angus, D.; Cook, D.; Cohen, J.; Opal, S.M.; Vincent, J.L.; Ramsay, G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference Intensive Care Med., 2003, 29(4), 530-538.
51. Bagshaw, S.M.; Uchino, S.; Bellomo, R.; Morimatsu, H.; Morgera, S.; Schetz, M.; Tan, I.; Bouman, C.; Macedo, E.; Gibney, N.; Tolwani, A.; Oudemans-van Straaten, H.M.; Ronco, C.; Kellum, J.A. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes Clin. J. Am. Soc. Nephrol., 2007, 2(3), 431-439.
52. Parrillo, J.E.; Parker, M.M.; Natanson, C.; Suffredini, A.F.; Danner, R.L.; Cunnion, R.E.; Ognibene, F.P. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern Med., 1990, 113(3), 227-242.
53. Di Giantomasso, D.; May, C.N.; Bellomo, R. Vital organ blood flow during hyperdynamic sepsis Chest, 2003, 124(3), 1053-1059.
54. Bosch, J.P.; Saccaggi, A.; Lauer, A.; Ronco, C.; Belledonne, M.; Glabman, S. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. Am. J. Med., 1983, 75(6), 943-950.
55. Castellino, P.; Giordano, C.; Perna, A.; De Fronzo, R.A. Effects of plasma amino acid and hormone levels on renal hemodynamics in humans Am. J. Physiol., 1988, 255(3 Pt 2), F444-449.
56. Thomas, D.M.; Coles, G.A.; Williams, J.D. What does the renal reserve mean? Kidney Int., 1994, 45(2), 411-416.
57. Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J.F.; Gerlach, H.; Harvey, M.; Marini, J.J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, B.T.; Townsend, S.; Vender, J.S.; Zimmerman, J.L.; Vincent, J.L. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med., 2008, 36(1), 296-327.
58. Rivers, E.; Nguyen, B.; Havstad, S.; Ressler, J.; Muzzin, A.; Knoblich, B.; Peterson, E.; Tomlanovich, M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med., 2001, 345(19), 1368-1377.
59. Di Giantomasso, D.; May, C.N.; Bellomo, R. Norepinephrine and vital organ blood flow. Intensive Care Med., 2002, 28(12), 1804-1809.
60. Di Giantomasso, D.; May, C.N.; Bellomo, R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med., 2003, 29(10), 1774-1781.
61. Girbes, A.R.; Patten, M.T.; McCloskey, B.V.; Groeneveld, A.B.; Hoogenberg, K. The renal and neurohumoral effects of the addition of low-dose dopamine in septic critically ill patients. Intensive Care Med., 2000, 26(11), 1685-1689.
62. Levy, B.; Nace, L.; Bollaert, P.E.; Dousset, B.; Mallie, J.P.; Larcan, A. Comparison of systemic and regional effects of dobutamine and dopexamine in norepinephrine-treated septic shock Intensive Care Med., 1999, 25(9), 942-948.
63. Wan, L.; Bellomo, R.; May, C.N. The effects of normal and hypertonic saline on regional blood flow and oxygen delivery. Anesth. Analg., 2007, 105(1), 141-147.
64. Joynt, G.M.; Lipman, J.; Gomersall, C.D.; Young, R.J.; Wong, E.L.; Gin, T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J. Antimicrob. Chemother., 2001, 47(4), 421-429.
65. Gomez, C.M.; Cordingly, J.J.; Palazzo, M.G. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob. Agents Chemother., 1999, 43(7), 1798-1802.
66. Roberts, J.A.; Roberts, M.S.; Robertson, T.A.; Dalley, A.J.; Lipman, J. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit. Care Med., 2009, 37(3), 926-933.
67. Boselli, E.; Breilh, D.; Saux, M.C.; Gordien, J.B.; Allaouchiche, B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia Intensive Care Med., 2006, 32(12), 2059-2062.
68. Brink, A.J.; Richards, G.A.; Schillack, V.; Kiem, S.; Schentag, J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis Int. J. Antimicrob. Agents, 2009, 33(5), 432-436.
69. Pea, F.; Porreca, L.; Baraldo, M.; Furlanut, M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J. Antimicrob. Chemother., 2000, 45(3), 329-335.
70. Conil, J.M.; Georges, B.; de Lussy, A.; Khachman, D.; Seguin, T.; Ruiz, S.; Cougot, P.; Fourcade, O.; Houin, G.; Saivin, S. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int. J. Antimicrob. Agents, 2008, 32(6), 505-510.
71. Pea, F.; Di Qual, E.; Cusenza, A.; Brollo, L.; Baldassarre, M.; Furlanut, M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilatorassociated pneumonia. Clin. Pharmacokinet, 2003, 42(6), 589-598.
72. Adembri, C.; Fallani, S.; Cassetta, M.I.; Arrigucci, S.; Ottaviano, A.; Pecile, P.; Mazzei, T.; De Gaudio, R.; Novelli, A. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int. J. Antimicrob. Agents, 2008, 31(2), 122-129.
73. Beckhouse, M.J.; Whyte, I.M.; Byth, P.L.; Napier, J.C.; Smith, A.J. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care, 1988, 16(4), 418-422.
74. Noel, G.; Strauss, R.; Shah, A.; Bagchi, P.; Group, B.S. In ICAAC/IDSA, 2008.
75. Brown, R.; Babcock, R.; Talbert, J.; Gruenberg, J.; Czurak, C.; Campbell, M. Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance Crit. Care Med., 1980, 8(2), 68-72.
76. Hanes, S.D.; Wood, G.C.; Herring, V.; Croce, M.A.; Fabian, T.C.; Pritchard, E.; Boucher, B.A. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am. J. Surg., 2000, 179(6), 436-440.
77. Shikuma, L.R.; Ackerman, B.H.; Weaver, R.H.; Solem, L.D.; Strate, R.G.; Cerra, F.B.; Zaske, D.E. Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit. Care Med., 1990, 18(1), 37-41.
78. Toschlog, E.A.; Blount, K.P.; Rotondo, M.F.; Sagraves, S.G.; Bard, M.R.; Schenarts, P.J.; Swanson, M.; Goettler, C.E. Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing. J. Trauma, 2003, 55(2), 255-260.
79. Albanese, J.; Leone, M.; Garnier, F.; Bourgoin, A.; Antonini, F.; Martin, C. Renal effects of norepinephrine in septic and nonseptic patients. Chest, 2004, 126(2), 534-539.
80. Benmalek, F.; Behforouz, N.; Benoist, J.F.; Lafay, M.; Mimoz, O.; Samii, K.; Edouard, A.R. Renal effects of low-dose dopamine during vasopressor therapy for posttraumatic intracranial hypertension. Intensive Care Med., 1999, 25(4), 399-405.
81. Vincent, F.; El-Khoury, N.; Bonnard, G.; Rondeau, E. Should a renal dose of norepinephrine stimulate hyperfiltration in head trauma patients? Chest, 2005, 127(6), 2282-2283.
82. Pea, F.; Viale, P.; Candoni, A.; Pavan, F.; Pagani, L.; Damiani, D.; Casini, M.; Furlanut, M. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin. Pharmacokinet, 2004, 43(6), 405-415.
83. Nyhlen, A.; Ljungberg, B.; Nilsson-Ehle, I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J. Infect. Dis., 2001, 33(3), 222-226.
84. Lamoth, F.; Buclin, T.; Csajka, C.; Pascual, A.; Calandra, T.; Marchetti, O. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob. Agents Chemother., 2009, 53(2), 785-787.
85. Romano, S.; Fdez de Gatta, M.M.; Calvo, M.V.; Caballero, D.; Dominguez-Gil, A.; Lanao, J.M. Population pharmacokinetics of amikacin in patients with haematological malignancies. J. Antimicrob. Chemother., 1999, 44(2), 235-242.
86. Higa, G.M.; Murray, W.E. Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin. Pharm. 1987, 6(12), 963-966.
87. Bubalo, J.S.; Munar, M.Y.; Cherala, G.; Hayes-Lattin, B.; Maziarz, R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever Antimicrob Agents Chemother, 2009, 53(2), 428-434.
88. Fernandez de Gatta, M.M.; Fruns, I.; Hernandez, J.M.; Caballero, D.; San Miguel, J.F.; Martinez Lanao, J.; Dominguez-Gil Hurle, A. Vancomycin pharmacokinetics and dosage requirements in hematologic. malignancies. Clin. Pharm., 1993, 12(7), 515-520.
89. Kohl, B.A.; Deutschman, C.S. The inflammatory response to surgery and trauma. Curr. Opin. Crit. Care, 2006, 12(4), 325-332.
90. Jacolot, A.; Incagnoli, P.; Edouard, A.R.; Tod, M.; Petitjean, O.; Samii, K.; Mimoz, O. Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome Intensive Care Med., 1999, 25(5), 486-491.
91. Ott, L.; McClain, C.J.; Gillespie, M.; Young, B. Cytokines and metabolic dysfunction after severe head injury. J. Neurotrauma, 1994, 11(5), 447-472.
92. Bratton, S.L.; Chestnut, R.M.; Ghajar, J.; McConnell Hammond, F.F.; Harris, O.A.; Hartl, R.; Manley, G.T.; Nemecek, A.; Newell, D.W.; Rosenthal, G.; Schouten, J.; Shutter, L.; Timmons, S.D.; Ullman, J.S.; Videtta, W.; Wilberger, J.E.; Wright, D.W. Guidelines for the management of severe traumatic brain injury. IX. Cerebral perfusion thresholds. J. Neurotrauma, 2007, 24 (Suppl 1), S59-64.
93. Bratton, S.L.; Chestnut, R.M.; Ghajar, J.; McConnell Hammond, F.F.; Harris, O.A.; Hartl, R.; Manley, G.T.; Nemecek, A.; Newell, D.W.; Rosenthal, G.; Schouten, J.; Shutter, L.; Timmons, S.D.; Ullman, J.S.; Videtta, W.; Wilberger, J.E.; Wright, D.W. Guidelines for the management of severe traumatic brain injury. I. Blood pressure and oxygenation. J. Neurotrauma, 2007, 24 (Suppl 1), S7-13.
94. Bratton, S.L.; Chestnut, R.M.; Ghajar, J.; McConnell Hammond, F.F.; Harris, O.A.; Hartl, R.; Manley, G.T.; Nemecek, A.; Newell, D.W.; Rosenthal, G.; Schouten, J.; Shutter, L.; Timmons, S.D.; Ullman, J.S.; Videtta, W.; Wilberger, J.E.; Wright, D.W. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J. Neurotrauma, 2007, 24 (Suppl 1),S14-20.
95. Udy, A.; Boots, R.; Senthuran, S.; Stuart, J.; Deans, R.; Lassig-Smith, M.; Lipman, J. Augmented creatinine clearance in traumatic brain injury. Anesth. Analg., 2010, 111(6),1505-1510.
96. Loirat, P.; Rohan, J.; Baillet, A.; Beaufils, F.; David, R.; Chapman, A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N. Engl. J. Med., 1978, 299(17), 915-919.
97. Bonapace, C.R.; White, R.L.; Friedrich, L.V.; Norcross, E.D.; Bosso, J.A. Pharmacokinetics of cefepime in patients with thermal burn injury. Antimicrob. Agents Chemother., 1999, 43(12), 2848-2854.
98. Conil, J.M.; Georges, B.; Lavit, M.; Laguerre, J.; Samii, K.; Houin, G.; Saivin, S. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br. J. Clin. Pharmacol., 2007, 64(1), 27-35.
99. Conil, J.M.; Georges, B.; Lavit, M.; Seguin, T.; Tack, I.; Samii, K.; Chabanon, G.; Houin, G.; Saivin, S. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int. J. Clin. Pharmacol. Ther., 2007, 45(10), 529-538.
100. Shikuma, L.R.; Ackerman, B.H.; Weaver, R.H.; Solem, L.D.; Strate, R.G.; Cerra, F.B.; Zaske, D.E. Thermal injury effects on drug disposition: a prospective study with piperacillin. J. Clin. Pharmacol., 1990, 30(7), 632-637.
101. Adam, D.; Zellner, P.R.; Koeppe, P.; Wesch, R. Pharmacokinetics of ticarcillin/clavulanate in severely burned patients. J. Antimicrob. Chemother., 1989, 24 (Suppl B), 121-129.
102. Dailly, E.; Kergueris, M.F.; Pannier, M.; Jolliet, P.; Bourin, M. Population pharmacokinetics of imipenem in burn patients. Fundam. Clin. Pharmacol., 2003, 17(6), 645-650.
103. Dolton, M.; Xu, H.; Cheong, E.; Maitz, P.; Kennedy, P.; Gottlieb, T.; Buono, E.; McLachlan, A.J. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns, 2010, 36(4),469-476.
104. Conil, J.M.; Georges, B.; Breden, A.; Segonds, C.; Lavit, M.; Seguin, T.; Coley, N.; Samii, K.; Chabanon, G.; Houin, G.; Saivin, S. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int. J. Antimicrob. Agents, 2006, 28(3), 226-230.
105. Mohr, J.F., 3rd; Ostrosky-Zeichner, L.; Wainright, D.J.; Parks, D.H.; Hollenbeck, T.C.; Ericsson, C.D. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob. Agents Chemother., 2008, 52(5), 1891-1893.
106. Garrelts, J.C.; Jost, G.; Kowalsky, S.F.; Krol, G.J.; Lettieri, J.T. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob. Agents Chemother., 1996, 40(5), 1153-1156.
107. Lortholary, O.; Lefort, A.; Tod, M.; Chomat, A.M.; Darras-Joly, C.; Cordonnier, C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect. Dis., 2008, 8(10), 612-620.
108. Craig, W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 1998, 26(1), 1-10.
109. Moore, R.D.; Lietman, P.S.; Smith, C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis., 1987, 155(1), 93-99.
110. Forrest, A.; Nix, D.E.; Ballow, C.H.; Goss, T.F.; Birmingham, M.C.; Schentag, J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother., 1993, 37(5), 1073-1081.
111. Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis., 2006, 42 (Suppl 1),S35-39.
112. Joukhadar, C.; Klein, N.; Mayer, B.X.; Kreischitz, N.; Delle-Karth, G.; Palkovits, P.; Heinz, G.; Muller, M. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit. Care Med., 2002, 30(7), 1478-1482.
113. Kitzes-Cohen, R.; Farin, D.; Piva, G.; De Myttenaere-Bursztein, S.A. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int. J. Antimicrob. Agents, 2002, 19(2), 105-110.
114. Lovering, A.M.; Vickery, C.J.; Watkin, D.S.; Leaper, D.; McMullin, C.M.; White, L.O.; Reeves, D.S.; MacGowan, A.P. The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. J. Antimicrob. Chemother, 1995, 36(1), 165-172.
115. Van Dalen, R.; Vree, T.; Baars, I.M. Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharmaceutisch Weekblad Scientific Edition, 1987, 9(2), 98-103.
116. Roos, J.F.; Lipman, J.; Kirkpatrick, C.M. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med., 2007, 33(5), 781-788.
117. Tam, V.H.; McKinnon, P.S.; Akins, R.L.; Drusano, G.L.; Rybak, M.J. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother., 2003, 47(6), 1853-1861.
118. Bustamante, C.I.; Drusano, G.L.; Tatem, B.A.; Standiford, H.C. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 1984, 26(5), 678-682.
119. Drusano, G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis., 2003, 36(Suppl 1), S42-50.
120. Turnidge J.D. The pharmacodynamics of beta-lactams Clin. Infect. Dis., 1998, 27(1), 10-22.
121. Vogelman, B.; Craig, W.A. Kinetics of antimicrobial activity J. Pediatr., 1986, 108(5 Pt 2), 835-840.
122. Vogelman, B.S.; Craig, W.A. Postantibiotic effects. J. Antimicrob. Chemother., 1985, 15 (Suppl A),37-46.
123. El Solh, A. Ceftobiprole: a new broad spectrum cephalosporin. Expert Opin. Pharmacother., 2009, 10(10), 1675-1686.
124. Roberts, J.A.; Boots, R.; Rickard, C.M.; Thomas, P.; Quinn, J.; Roberts, D.M.; Richards, B.; Lipman, J. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J. Antimicrob. Chemother., 2007, 59(2), 285-291.
125. Lipman, J.; Gomersall, C.D.; Gin, T.; Joynt, G.M.; Young, R.J. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J. Antimicrob. Chemother., 1999, 43(2), 309-311.
126. Georges, B.; Conil, J.M.; Cougot, P.; Decun, J.F.; Archambaud, M.; Seguin, T.; Chabanon, G.; Virenque, C.; Houin, G.; Saivin, S. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int. J. Clin. Pharmacol. Ther., 2005, 43(8), 360-369.
127. McNabb, J.J.; Nightingale, C.H.; Quintiliani, R.; Nicolau, D.P. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy, 2001, 21(5), 549-555.
128. Mouton, J.W.; Vinks, A.A.; Punt, N.C. Pharmacokineticpharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother., 1997, 41(4), 733-738.
129. Nicolau, D.P.; McNabb, J.; Lacy, M.K.; Quintiliani, R.; Nightingale, C.H. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int. J. Antimicrob. Agents, 2001, 17(6), 497-504.
130. Roberts, J.A.; Paratz, J.; Paratz, E.; Krueger, W.A.; Lipman, J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int. J. Antimicrob. Agents, 2007, 30(1), 11-18.
131. Lodise, T.P., Jr.; Lomaestro, B.; Drusano, G.L. Piperacillintazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis., 2007, 44(3), 357-363.
132. Lorente, L.; Lorenzo, L.; Martin, M.M.; Jimenez, A.; Mora, M.L. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann. Pharmacother., 2006, 40(2), 219-223.
133. Lorente, L.; Jimenez, A.; Martin, M.M.; Iribarren, J.L.; Jimenez, J.J.; Mora, M.L. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int. J. Antimicrob. Agents, 2009, 33(5), 464-468.
134. Lorente, L.; Jimenez, A.; Palmero, S.; Jimenez, J.J.; Iribarren, J.L.; Santana, M.; Martin, M.M.; Mora, M.L. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin. Ther., 2007, 29(11), 2433-2439.
135. Roberts, J.A.; Webb, S.; Paterson, D.; Ho, K.M.; Lipman, J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit. Care Med., 2009, 37(6), 2071-2078.
136. MacGowan, A.P. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother., 2003, 51 (Suppl 2),ii17-25.
137. Brier, M.E.; Stalker, D.J.; Aronoff, G.R.; Batts, D.H.; Ryan, K.K.; O'Grady, M.; Hopkins, N.K.; Jungbluth, G.L. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Chemother., 2003, 47(9), 2775-2780.
138. Andes, D.; van Ogtrop, M.L.; Peng, J.; Craig, W.A. In vivo pharmacodynamics of a new oxazolidinone (linezolid) Antimicrob. Agents Chemother., 2002, 46(11), 3484-3489.
139. Gentry-Nielsen, M.J.; Olsen, K.M.; Preheim, L.C. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob. Agents Chemother., 2002, 46(5), 1345-1351.
140. Thallinger, C.; Buerger, C.; Plock, N.; Kljucar, S.; Wuenscher, S.; Sauermann, R.; Kloft, C.; Joukhadar, C. Effect of severity of sepsis on tissue concentrations of linezolid. J. Antimicrob. Chemother., 2008, 61(1), 173-176.
141. Chambers, H.E.; Sande, M.A. In: Goodman and Gillman's The pharmacological basis of therapeutics; McGraw Hill: New York, 1996, pp. 1103-1121.
142. Kashuba, A.D.; Nafziger, A.N.; Drusano, G.L.; Bertino, J.S., Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob. Agents Chemother., 1999, 43(3), 623-629.
143. Olsen, K.M.; Rudis, M.I.; Rebuck, J.A.; Hara, J.; Gelmont, D.; Mehdian, R.; Nelson, C.; Rupp, M.E. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit. Care Med., 2004, 32(8), 1678-1682.
144. Prins, J.M.; Buller, H.R.; Kuijper, E.J.; Tange, R.A.; Speelman, P. Once versus thrice daily gentamicin in patients with serious infections. Lancet, 1993, 341(8841), 335-339.
145. Lugo, G.; Castaneda-Hernandez, G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit. Care Med., 1997, 25(5), 806-811.
146. Rea, R.S.; Capitano, B.; Bies, R.; Bigos, K.L.; Smith, R.; Lee, H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit., 2008, 30(6), 674-681.
147. Schriever, C.A.; Fernandez, C.; Rodvold, K.A.; Danziger, L.H. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm., 2005, 62(11), 1145-1158.
148. Safdar, N.; Andes, D.; Craig, W.A. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother., 2004, 48(1), 63-68.
149. W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am, 2003, 17(3), 479-501.
150. Moise-Broder, P.A.; Forrest, A.; Birmingham, M.C.; Schentag, J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet, 2004, 43(13), 925-942.
151. Wysocki, M.; Delatour, F.; Faurisson, F.; Rauss, A.; Pean, Y.; Misset, B.; Thomas, F.; Timsit, J.F.; Similowski, T.; Mentec, H.; Mier, L.; Dreyfuss, D. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother., 2001, 45(9), 2460-2467.
152. Rello, J.; Sole-Violan, J.; Sa-Borges, M.; Garnacho-Montero, J.; Munoz, E.; Sirgo, G.; Olona, M.; Diaz, E. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med., 2005, 33(9), 1983-1987.
153. Del Favero, A.; Patoia, L.; Rosina, R.; Buniva, G.; Danese, A.; Bernareggi, A.; Molini, E.; Cavenaghi, L. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob. Agents Chemother., 1991, 35(12), 2551-2557.
154. Brink, A.J.; Richards, G.A.; Cummins, R.R.; Lambson, J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int. J. Antimicrob. Agents, 2008, 32(5), 455-458.
155. A.P. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet, 2000, 39(3), 167-183.
156. Mimoz, O.; Rolland, D.; Adoun, M.; Marchand, S.; Breilh, D.; Brumpt, I.; Debaene, B.; Couet, W. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med., 2006, 32(5), 775-779.
157. Preston, S.L.; Drusano, G.L.; Berman, A.L.; Fowler, C.L.; Chow, A.T.; Dornseif, B.; Reichl, V.; Natarajan, J.; Corrado, M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA, 1998, 279(2), 125-129.
158. Thomas, J.K.; Forrest, A.; Bhavnani, S.M.; Hyatt, J.M.; Cheng, A.; Ballow, C.H.; Schentag, J.J. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother., 1998, 42(3), 521-527.
159. Lipman, J.; Scribante, J.; Gous, A.G.; Hon, H.; Tshukutsoane, S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob. Agents Chemother., 1998, 42(9), 2235-2239.
160. Sun, H.K.; Kuti, J.L.; Nicolau, D.P. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit. Care Med., 2005, 33(10), 2222-2227.
161. Graninger, W.; Zeitlinger, M. Clinical applications of levofloxacin for severe infections. Chemotherapy, 2004, 50 (Suppl 1),16-21.